[Improving longevity in advanced intestinal cancer].
Schmoll
Hans-Joachim
HJ
Direktorder Universitätsklinik, und Poliklinik für Innere Medizin IV, Martin-Luther-Universität, Halle-Wittenberg, Klinikum der Medizinischen Fakultät, 06120 Halle(Saale).
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D017326:Clinical Trials, Phase III as Topic / Q000451:nursing; D015179:Colorectal Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000401:mortality / Q000451:nursing*; D018572:Disease-Free Survival; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic / Q000451:nursing
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin